Analysts Anticipate Syros Pharmaceuticals Inc (SYRS) to Announce -$0.45 Earnings Per Share

Share on StockTwits

Wall Street brokerages predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will report earnings per share (EPS) of ($0.45) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Syros Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.43). Syros Pharmaceuticals reported earnings per share of ($0.53) during the same quarter last year, which indicates a positive year over year growth rate of 15.1%. The business is expected to issue its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.85) per share for the current financial year, with EPS estimates ranging from ($1.92) to ($1.77). For the next financial year, analysts expect that the company will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.67). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Friday, August 10th. The company reported ($0.43) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07. The company had revenue of $0.38 million during the quarter, compared to analyst estimates of $1.33 million.

A number of research firms have recently commented on SYRS. BidaskClub upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 31st. Cann restated a “buy” rating and set a $26.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, August 7th. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Friday, August 10th. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Tuesday, July 17th. Finally, HC Wainwright restated a “hold” rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. Syros Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $19.29.

Large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new stake in Syros Pharmaceuticals in the 2nd quarter valued at about $119,000. MetLife Investment Advisors LLC acquired a new stake in Syros Pharmaceuticals in the 2nd quarter valued at about $134,000. The Manufacturers Life Insurance Company lifted its stake in Syros Pharmaceuticals by 299.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after purchasing an additional 9,691 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Syros Pharmaceuticals in the 2nd quarter valued at about $177,000. Finally, Citadel Advisors LLC acquired a new stake in Syros Pharmaceuticals in the 2nd quarter valued at about $186,000. Institutional investors and hedge funds own 60.70% of the company’s stock.

NASDAQ SYRS traded down $0.27 on Friday, reaching $7.61. The company had a trading volume of 179,167 shares, compared to its average volume of 187,573. The firm has a market cap of $400.82 million, a PE ratio of -3.57 and a beta of -1.96. Syros Pharmaceuticals has a 1-year low of $6.30 and a 1-year high of $17.50.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Read More: What are the benefits of buying treasury bonds?

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply